Press Release
atai Life Sciences to Participate in Upcoming February Investor Conference
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February.
February 15, 2022
Press Release
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets
January 27, 2022
Press Release
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
• Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in
January 12, 2022
Press Release
atai Life Sciences to Participate in Upcoming January Investor Conference
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: H.C.
January 10, 2022
Press Release
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help unlock the mysteries of the brain, improve the treatment of mental health conditions and positively
December 16, 2021
Press Release
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai’s diversified platform and multiple innovative programs
December 15, 2021
Displaying 55 - 60 of 106